About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Not Yet Recruiting

PARPi and Ovarian Cancer Survival

Effect of PARP Inhibitors Maintenance Therapy on the Survival Rate of Advanced or Relapsed Epitherlial Ovarian Cancer: an Observational Cohort Study

NCT06838429•Shanghai Gynecologic Oncology Group

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Epithelial Ovarian Cancer, Fallopian Tube or PeritoneumPARP Inhibitor

Key Dates

Start Date

March 1, 2025

Primary Completion Date

March 1, 2026

Completion Date

March 1, 2026

Last Updated

February 20, 2025

Related Studies

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

NCT06710548

Ovarian CancerAdvanced Ovarian Carcinoma+5 more

Active Not Recruiting

The HER Project: HRD in EGFR-mutated NSCLC

NCT07303218

EGFRNon Small Cell Lung Cancer+2 more

Not Yet RecruitingPhase 2

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

NCT06055166

PARP Inhibitor for Esophageal Squamous Cell Carcinoma

Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

NCT04566952

Ovarian CancerOvarian and Fallopian Tube Cysts and Neoplasms+17 more

Sponsors

Lead Sponsor

Shanghai Gynecologic Oncology Group

Collaborators

Institute for Ovarian Cancer, Fudan University; Department of Gynecologic Oncology, Cancer Center, Fudan University Zhongshan Hospital, Shanghai, China
Department of Gynecologic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University
Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 20, 2025Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions